From: Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis
# | Group of subjects | Estimation | Number of subjects (N) | Source |
---|---|---|---|---|
1 | Italian population, ≥ 12 years | – | 5,41,19,490 | ISTAT 2019 [43] |
2 | Patients with asthma | 6.10% of #1 | 33,01,289 | [41] |
3 | Patients with asthma exemption code | 36.29% of #2 | 11,97,821 | |
4 | Patients with spirometry (last 12Â months) | 27.74% of #3 | 3,32,281 | |
5 | Patients treated with ICS | 46.95% of #4 | 1,55,997 | |
6 | Patients treated with high-dose ICS | 43.05% of #5 | 67,151 | |
7 | Patients treated with high-dose ICS, adherent | 57.20% of #6 | 38,410 | |
8 | Uncontrolled patients with ≥ 2 exacerbations/year* | 47.57% of #7 | 18,270 | |
9 | Uncontrolled patients with severe asthma | 0.04% of #1 | 21,649 | [39] |
10 | Average number uncontrolled patients with severe asthma | Average of #8 and #9 | 19,960 | Calculated |